Axial3D, a leading medical segmentation and 3D solutions company, has achieved a significant milestone in the healthcare industry with its latest FDA clearance. The company has become the first to receive FDA clearance for its automated, AI-driven, cloud-based segmentation platform designed for orthopedic trauma, orthopedic, maxillofacial, and cardiovascular applications. This is the second FDA clearance for Axial3D’s platform, INSIGHT™, and it is expected to revolutionize personalized healthcare by leveraging artificial intelligence and automation.
The cloud-based solution developed by Axial3D aims to advance personalized healthcare by providing scalable, personalized 3D solutions. By utilizing AWS cloud infrastructure, AI algorithms, and advanced machine learning techniques, their platform automates the conversion process of 2D DICOM images, such as CT and MRI scans, into accurate 3D visualizations. These visualizations can be used to create 3D print-ready files, 3D mesh files, or 3D printed anatomical models using Stratasys print technology.
One of the key benefits of Axial3D INSIGHT™ is its ability to automate the traditionally time-consuming and labor-intensive task of manual or semi-manual image segmentation. This automation allows healthcare providers and medical device companies to address more applications while saving significant amounts of time. By streamlining the segmentation process, Axial3D enables healthcare professionals to enhance diagnostic accuracy, treatment planning, and surgical intervention.
The FDA clearance for Axial3D INSIGHT™ is a testament to the company’s commitment to pushing the boundaries of innovation in healthcare. According to Dan Crawford, Founder and CSO of Axial3D, this achievement showcases their dedication in delivering exceptional patient care through advanced automation, artificial intelligence, and machine learning technologies. The clearance is expected to provide a major boost to medical device companies looking to scale up their production processes.
In addition to benefiting healthcare providers, Axial3D’s platform also offers advantages for medical device companies. By implementing automation and AI into their workflows, these companies can process more patient data with the same resources, allowing for the design of personalized devices and surgical kits. These devices and kits can include surgical plans, models, and surgical guides, which can then be 3D printed on a variety of printers, including Stratasys systems.
Axial3D’s partnership with Stratasys has been instrumental in advancing their technology and bringing a joint solution to the market. Stratasys, a leading provider of 3D printing solutions, sees great value in Axial3D’s segmentation platform and its ability to transform the healthcare landscape. The FDA clearance is seen as a significant achievement, leveraging automation and AI as key business drivers in the medical sector.
In conclusion, Axial3D’s FDA clearance for their AI-driven, cloud-based segmentation platform represents a major milestone for personalized healthcare. By automating the conversion of 2D medical images into 3D visualizations, Axial3D empowers healthcare professionals and medical device companies to enhance patient care, improve diagnostic accuracy, and streamline production processes. With their commitment to innovation and dedication to leveraging advanced technologies, Axial3D is poised to make personalized healthcare at scale a reality.
